New hope for transplant survivors with rare lung disease
NCT ID NCT03805477
First seen Jan 09, 2026 · Last updated Apr 30, 2026 · Updated 14 times
Summary
This study tests a drug called nintedanib in 20 people who developed a serious lung condition (bronchiolitis obliterans syndrome) after a stem cell transplant. The drug is added to their regular immune-suppressing medicines for 12 months. The main goal is to see if the drug is safe and tolerable, and to check if it helps slow down lung function decline.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS SYNDROME (BOS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinic of Hematology, University Hospital Basel
RECRUITINGBasel, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Clinic of Respiratory Medicine, University Hospital Basel
RECRUITINGBasel, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
King Faisal Specialist Hospital & Research Centre
RECRUITINGRiyadh, 11471, Saudi Arabia
Contact
Conditions
Explore the condition pages connected to this study.